礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批

医药经济报11-22

礼来的替尔泊肽在国内报上市今日，CDE 官网显示，替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。替尔泊肽注射液（Tirzepatide）是首款治疗 2 型糖尿病的 GLP-1R /GIPR 双靶点降糖药，每周一次给药，曾在大型 III 期临床中头对头击败司美格鲁肽，引发热议。在美国，于 2022 年 5 月获批上市用于治疗 2 型糖尿病（T2DM），去年年底又获批减重适应症...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485234953?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-22 17:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485234953","market":"us","top_or_hot":-1,"title":"礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批","media":"医药经济报","content":"<div>\n<p>礼来的替尔泊肽在国内报上市今日，CDE 官网显示，替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。替尔泊肽注射液（Tirzepatide）是首款治疗 2 型糖尿病的 GLP-1R /GIPR 双靶点降糖药，每周一次给药，曾在大型 III 期临床中头对头击败司美格鲁肽，引发热议。在美国，于 2022 年 5 月获批上市用于治疗 2 型糖尿病（T2DM），去年年底又获批减重适应症...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 17:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b><strong>医药经济报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼来的替尔泊肽在国内报上市今日，CDE 官网显示，替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。替尔泊肽注射液（Tirzepatide）是首款治疗 2 型糖尿病的 GLP-1R /GIPR 双靶点降糖药，每周一次给药，曾在大型 III 期临床中头对头击败司美格鲁肽，引发热议。在美国，于 2022 年 5 月获批上市用于治疗 2 型糖尿病（T2DM），去年年底又获批减重适应症...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0122379950.USD","symbol_name":"贝莱德世界健康科学A2","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b","article_id":"2485234953","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485234953","pubTimestamp":1732267045,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"阿斯利康和安进的TSLP 单抗国内报上市今日，CDE 官网显示，阿斯利康和安进联合递交了 TSLP 单抗特泽利尤单抗注射液的上市申请。这些患者的 TSLP 表达增加，并且与疾病严重程度相关。阻断 TSLP 可能会阻止免疫细胞释放促炎细胞因子，从而预防病情恶化并改善疾病控制。它是一款 first-in-class TSLP单抗，此前已在美国、欧盟、日本地区获批上市，用于治疗哮喘。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0122379950.USD":"贝莱德世界健康科学A2","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4581":"高盛持仓","TSLP":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LLY":"礼来","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","AMGN":"安进","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4007":"制药","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","AZN":"阿斯利康","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","MRK":"默沙东","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC"},"translate_title":"Eli Lilly's Tilpotide, AstraZeneca and Amgen's TSLP monoclonal antibodies were reported for listing in China, and Merck's new anti-tumor drug was approved in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"TSLP":1,"MRK":1,"LLY":1,"AMGN":1},"content_text":"礼来的替尔泊肽在国内报上市今日，CDE 官网显示，替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。替尔泊肽注射液（Tirzepatide）是首款治疗 2 型糖尿病的 GLP-1R /GIPR 双靶点降糖药，每周一次给药，曾在大型 III 期临床中头对头击败司美格鲁肽，引发热议。在美国，于 2022 年 5 月获批上市用于治疗 2 型糖尿病（T2DM），去年年底又获批减重适应症。这款药物于今年 5 月和 7 月先后在国内获批 T2DM 和肥胖。此外还有一个适应症也已在国内报上市，推测是用于治疗中度至重度阻塞性睡眠呼吸暂停和肥胖患者。阿斯利康和安进的TSLP 单抗国内报上市今日，CDE 官网显示，阿斯利康和安进联合递交了 TSLP 单抗特泽利尤单抗注射液的上市申请。根据该药的临床研究进度，推测其本次申报的适应症可能是哮喘。在国内，特泽利尤单抗已完成一项治疗哮喘的 Ⅲ 期临床， 给药频率为每 4 周一次，皮下注射给药。TSLP 是一种关键的上皮细胞因子，它位于多个炎症级联信号的顶端，在与严重哮喘和其他炎症疾病相关的过敏性、嗜酸性和其他类型的内皮炎症的启动和持续中扮演着至关重要的作用。TSLP 是在与哮喘、慢性鼻窦炎伴鼻息肉、慢性阻塞性肺病、嗜酸性食管炎和其他疾病相关的多种触发因素的反应下释放的。这些患者的 TSLP 表达增加，并且与疾病严重程度相关。阻断 TSLP 可能会阻止免疫细胞释放促炎细胞因子，从而预防病情恶化并改善疾病控制。研究表明，针对气道上皮释放的 TSLP 可能是未来治疗下呼吸道疾病的潜在方法。特泽利尤单抗（Tezepelumab）由阿斯利康和安进联合开发。它是一款 first-in-class TSLP单抗，此前已在美国、欧盟、日本地区获批上市，用于治疗哮喘。默沙东抗肿瘤新药国内获批近日，NMPA 官网显示，默沙东 HIF-2α 抑制剂贝组替凡（Belzutifan）在国内获批，用于 VHL（von Hippel-Lindau）病相关肾细胞癌（RCC）、中枢神经系统（CNS）血管母细胞瘤或胰腺神经内分泌肿瘤（pNET）。贝组替凡最初由 Peloton Therapeutics 开发，2019 年 5 月默沙东以 10.5 亿美元首付款、11.5 亿美元里程碑款项的高价收购了 Peloton Therapeutics 公司，获得了贝组替凡。HIF 即缺氧诱导因子，是肾细胞癌中的关键致癌驱动因子，作为一款 HIF-2α 抑制剂，贝组替凡通过阻断 HIF-2α 和 HIF-1β 的异二聚体化，来阻断细胞生长、增殖以及阻止异常血管形成，从而实现抗癌疗效。编辑：晚晚Biotech整合大提速！睿跃生物借壳，葆元医药、依生生物之后纳斯达克再迎中国浪潮？吉利德肿瘤药卖不动了？新药失利、裁员调整，并购豪赌如何翻盘？并购潮涌！中生、康缘、东北等连续出手，行业整合加速？医保创新结算方式、建立预付金制度，医院回款难破冰www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《医药经济报》学术公众号聚焦肿瘤学术前沿长按关注免疫时间《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485234953"}